Curbside Consults: Applying Real World Evidence to Practice When Selecting Treatment for nAMD

Author(s)/Faculty: Rishi P. Singh, MD; Glenn C. Yiu, MD, PhD
Release Date: 5/31/2021Expiration Date: 5/30/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.25
Content Type: VideoProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering numerous patients delayed or arrested disease progression, as well as the possibility of regaining lost vision. The discovery that intravitreal therapy can be effective in treating neovascular AMD (nAMD) has spurred further research exploring the outcomes of treatment regimens using this approach. Further, newer protocols that allow for longer intervals between treatments are now available and hold promise in lessening the treatment burden. Yet, ophthalmologists are challenged to select the most appropriate dosing regimen and are unsure of the effects of residual retinal fluid after treatment. In this Curbside Consults continuing medical education activity, expert clinicians discuss a challenging case in the management of a patient with nAMD.